An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Xcopri

Chemical Namecenobamate
Dosage FormTablet (oral; 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg)
Drug ClassInhibitors
SystemNervous
CompanySK Life Science
Approval Year2019

Indication

  • Xcopri is indicated for the treatment of partial-onset seizures in adult patients.
Last updated on 10/30/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xcopri (cenobamate) Prescribing Information2020SK Life Sciences
Document TitleYearSource
Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures2020Neurology
Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial2019The Lancet Neurology